ArsenalBio

Executive Summary

ArsenalBio is a private biotechnology company pioneering the development of programmable T cell therapies for solid tumors. The company leverages CRISPR gene editing, synthetic biology, and computational tools to design T cells that can overcome key limitations in current cell therapy, such as poor tumor infiltration, limited persistence, and immunosuppressive tumor microenvironments. Founded in 2019 and headquartered in South San Francisco, ArsenalBio has raised approximately $325 million in funding, reflecting strong investor confidence in its platform. The company is currently in Phase 1 clinical development, advancing its lead programs toward proof-of-concept data. With a growing team of 200–500 employees, ArsenalBio is at a pivotal stage, aiming to demonstrate clinical efficacy in solid tumors, a historically challenging area for cell therapy. Its integrated approach positions it as a potential leader in the next generation of adoptive cell therapies.

Upcoming Catalysts (preview)

• H2 2026Phase 1 Clinical Data Readout for Lead Program (AB-101)40% success
• 2027Initiation of Phase 2 Trial or Expansion Cohort35% success
• 2026–2027Strategic Partnership or Licensing Deal for Solid Tumor Indications50% success